TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03767556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Powerbreathe® K5
Study: NCT00894790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral Diclofenac
Description: diclofenac 75 mg tablet BID (twice a day)
Study: NCT02849392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pistachio added 20% of kcals to diet
Description: Pistachio added 20% of kcals to diet
Study: NCT02101359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2380
Description: 200 microlitres of T2380 will be administrated intracamerally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mydriatics
Description: 3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine
Description: Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
Study: NCT04660708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manual physical therapy
Description: Previously described in the arm description
Study: NCT01876979

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IMF Screws
Description: stainless steel screws placed in bone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erich Arch Bars
Description: Surgical braces wired around teeth
Study: NCT01627301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device-Guided Breathing (DGB)
Description: The RESPeRATE device will be used for 15 minutes of device-guided breathing daily for 8 weeks. The participant places the elastic belt with a respiration sensor around the upper abdomen, and wears earbuds for audio feedback. The device monitors the breathing rate, calculates inspiration and expiration times, and generates a personalized melody of two distinct ascending and descending tones for inhalation versus exhalation. Users effortlessly entrain their breathing pattern with the tones, and the device gradually guides the user to a prolonged expiration time and slower respiratory rate (to \< 10 breaths/minute). The device automatically stores usage data, allowing for quantification of adherence and performance.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham DGB
Description: The sham device is identical to the DGB device, except it does not guide respiratory rates to slow down and instead maintains a rate of 14 breaths per minute. The sham device is used for 15 minutes per day for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: tVNS is a noninvasive method that involves placing a device over the skin overlying the vagus nerve on the neck. The device delivers mild electrical stimulation, using transcutaneous electrical nerve stimulation (TENS) unit. The stimulation is increased until there is a vibration and slight muscle contraction in the lower face or neck. Then the stimulation is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes. The tVNS device is used twice daily for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tVNS
Description: Sham stimulation is delivered using a device that is identical to the gammaCore device but is programed to deliver a lower frequency that can be felt by the participant but does not actually stimulate the vagus nerve. The sham device is used twice daily for 8 weeks.
Study: NCT01841567

Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex border post. op

Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex border post op
Study: NCT01451697

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control (Placebo)
Description: The control condition will involve relaxation training.
Study: NCT01388478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-pramipexole
Description: R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
Study: NCT04668534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS 10
Description: Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS 25
Description: Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)
Study: NCT01359878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate
Description: 2 gram intra venous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: Isotonic saline in equivalent volume - 100 ml
Study: NCT00683397

Intervention type: OTHER
Intervention: Blood sampling
Description: Screening of thrombophilia
Study: NCT01589107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video decision aid
Study: NCT04515641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Two ISL 30 mg capsules taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Two ISL 30 mg capsules taken by mouth.
Study: NCT00316862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo Surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation
Study: NCT01230684

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)
Description: The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
Study: NCT03399682

Intervention type: DIAGNOSTIC_TEST
Intervention: cystography
Description: observationnal study
Study: NCT04463732

Intervention type: OTHER
Intervention: Loaded inspiratory muscle test and cardiopulmonary exercise test
Description: This is an observational study. Loaded inspiratory muscle test is setting at 30% of maximal inspiratory pressure. Subjects will perform only 15 breaths under this intensity to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training. Cardiopulmonary exercise test is performed by using bicycle ergometer. These two tests will be performed at least 1 week separately.
Study: NCT00556205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenously every 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenously every 14 days
Study: NCT03903003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal oxygen device (POİNT)
Description: With POINT device (peri-operative insufflatory nasal therapy); patients are heated at higher flow and applied to humidified oxygen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face mask
Description: In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
Study: NCT01729533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMSI
Description: Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei (\[1\] smooth, \[2\] symmetric, and \[3\] oval configuration) and \[4\] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies \<4% of the nuclear area) are selected for injection.
Study: NCT03808025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: opioid education
Description: see arm/group descriptions
Study: NCT02934087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Aneurysm Repair
Description: Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Aneurysm Repair
Description: Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
Study: NCT01606748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2
Study: NCT03216148

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FET-PET
Description: All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
Study: NCT02028403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936559
Description: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936559
Description: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936559
Description: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936559
Description: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-936559
Description: Sodium chloride for injection 0.9%, USP, administered as an IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-936559
Description: Sodium chloride for injection 0.9%, USP, administered as an IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-936559
Description: Sodium chloride for injection 0.9%, USP, administered as an IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-936559
Description: Sodium chloride for injection 0.9%, USP, administered as an IV infusion
Study: NCT02105389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Yoga Intervention
Study: NCT02334176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided axillary plexus block with 1 injection
Description: The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided axillary plexus block with 2 injections
Description: The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 1.5% with epinephrine 5µg/ml
Description: 35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 1.5% with epinephrine 5µg/ml
Description: 35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
Study: NCT01904318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 40 mg
Description: IDP-73152 mesylate 40 mg single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 80 mg
Description: IDP-73152 mesylate 80 mg single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 160 mg
Description: IDP-73152 mesylate 160 mg single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 320 mg
Description: IDP-73152 mesylate 320 mg single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 640 mg
Description: IDP-73152 mesylate 640 mg single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 1280 mg
Description: IDP-73152 mesylate 1280 mg single dose administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose administration
Study: NCT04794413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
Study: NCT00630747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Idursulfase
Description: Solution for intravenous infusion, 0.5 mg/kg once-weekly
Study: NCT03499405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigator Intervention
Description: Caregivers will be paired with a culturally matched family navigator.
Study: NCT04620954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: 2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.
Study: NCT01590732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study: NCT04276610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Reading Rehabilitation
Description: Following Time 1, participants will receive the full complement of vision rehabilitation services available and deemed suitable by their clinical staff and rehabilitation professionals of either rehabilitation centre, according to the provision of assistive devices and services regulated by the Quebec Health Insurance (RAMQ). These services are include but are not limited to: a full optometric exam to determine functional vision, including refraction and the prescription of appropriate near and distance glasses and optical devices, an assessment by a low vision therapist and/or occupational therapist, the loan provision of hand-held optical magnification devices, electronic non-optical magnification devices (e.g., portable or table-top closed-circuit televisions), or computer software for screen content magnification (e.g., ZoomText), with appropriate training and follow-up sessions in the home, if required.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Reading Rehabilitation
Description: Following Time 1, participants will receive the full complement of vision rehabilitation services available and deemed suitable by their clinical staff and rehabilitation professionals of either rehabilitation centre, according to the provision of assistive devices and services regulated by the Quebec Health Insurance (RAMQ). These services are include but are not limited to: a full optometric exam to determine functional vision, including refraction and the prescription of appropriate near and distance glasses and optical devices, an assessment by a low vision therapist and/or occupational therapist, the loan provision of hand-held optical magnification devices, electronic non-optical magnification devices (e.g., portable or table-top closed-circuit televisions), or computer software for screen content magnification (e.g., ZoomText), with appropriate training and follow-up sessions in the home, if required.
Study: NCT03690973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar socket preservation with graft and flap surgery
Description: Alveolar socket preservation with xenogenic bone graft and flap surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with bone using flapless surgery
Description: Immediate implant placement with xenogenic bone graft using flapless surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with bone using flap surgery
Description: Immediate implant placement with xenogenic bone graft using flap surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveolar socket preservation with graft and flapless surgery
Description: Alveolar socket preservation with xenogenic bone graft and flapless surgery
Study: NCT03055468

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer support
Description: Peer support and antidepressant medications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Peer support and antidepressant medications
Study: NCT02188277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.